Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22810539 | 0.83 | SLC6A2 (0.40) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL2072547 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4HTR2AHRH1SLC6A3 | |
| SCHEMBL3862440 | 0.79 | RECQL (0.42) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL21311151 | 0.79 | ASAH1 (0.45) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL6176042 | 0.78 | KMO (0.43) | SLC6A2HTR2AKMORECQLMEN1 | |
| SCHEMBL29350890 | 0.75 | RECQL (0.43) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL878425 | 0.75 | RECQL (0.43) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL20622947 | 0.72 | RECQL (0.41) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL21276545 | 0.72 | RECQL (0.41) | SLC6A2KMORECQLMEN1NPC1 | |
| SCHEMBL29311539 | 0.72 | RECQL (0.41) | SLC6A2KMORECQLMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | SLC6A2 4271/4885SLC6A4 4101/4885HTR2A 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.